- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04018729
Cell Therapy Associated With Endobronchial Valve (CEL&VAL)
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy Associated With Unidirectional Endobronchial Valve in Patients With Severe Pulmonary Emphysema: A Randomized Clinical Trial
Chronic obstructive pulmonary disease (COPD) is one of the most common diseases worldwide and is considered a public health problem. The World Health Organization estimates that about 210 million people have COPD. Disease-related mortality is more than 3 million, representing 5% of all deaths, 90% of this mortality being concentrated in middle- and low-income countries. COPD can be subdivided into chronic bronchitis and emphysema. Emphysema, the focus of this project, is histologically defined by the permanent increase of the distal air spaces to the terminal bronchioles associated with the destruction of the alveolar septa in the lung. Approximately two-thirds of adult men and a quarter of women (most without dysfunction) will have well-defined emphysema, but often of limited extent.
Mesenchymal stem cells (MSCs) have anti-inflammatory, anti-fibrotic, microbicide and repair potential. Regarding COPD, several authors have concentrated efforts in the investigation of the relationship between the severity of the condition and the various sources of adult stem cells. Apparently the lungs have a high chemotactic effect in relation to adult stem cells, since several studies have evidenced a high implantation (6-20%) of stem cells derived from bone marrow, administered systemically, in the pulmonary tissue of receptors. Therefore, MSCs has been tested in different lung diseases have no effective treatment, such as pulmonary fibrosis, acute respiratory distress syndrome, asthma, COPD positive results, such as reduction of fibrosis, reduction of proliferation inflammatory cells and cytokines, reduction of infectious processes and recovery of the histological changes caused by pulmonary emphysema.
Based on these findings, the purpose of this project is to evaluate the safety and efficacy of endoscopic administration of bone marrow stem cells in patients with severe homogeneous emphysema and evaluating the feasibility, efficacy and safety of this procedure.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Hugo G Oliveira, PhD
- Phone Number: 8241 +55 51 3359-8241
- Email: hugo@hugooliveira.org
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035903
- Recruiting
- Hospital de Clinicas de Porto Alegre
-
Contact:
- Hugo G Oliveira, PhD
- Phone Number: 55 51 3359-1337
- Email: holiveira@hcpa.edu.br
-
Contact:
- Igor G Benedetto, MSc
- Phone Number: 55 51 3359-1337
- Email: ibenedetto@hcpa.edu.br
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of severe heterogeneous pulmonary emphysema (at least 10% of total lung parenchyma or 25% of target lobe with density < -950HU);
- Heterogeneity> 15pp (difference of at least 15 percentage points of lung parenchyma with density greater than -950HU between the treated lobe(s) and the remaining lung on the same side)
- Estimates of low or non-existent collateral ventilation (fissure integrity> 95% measured by VIDA Diagnostics or collateral ventilation measured by negative Chartis® System)
- Total lung capacity> 100% of predicted
- Residual volume> 175% of predicted
- FEV1 <50% of predicted post-bronchodilator
- DLCO (diffusing capacity of the lungs for carbon monoxide) <45% of predicted post-bronchodilator
- Body Mass Index (BMI) Greater than 18Kg/m2 and less than 35Kg/m2.
- Optimized clinical treatment
- Daily physical activities limitation
- Possibility of pulmonary rehabilitation
- Preserved ventricular function (LVEF> 40%)
- Cessation of smoking ≥ 4 months
- Dyspnea MMRC ≥ 2
Exclusion Criteria:
- Homogeneous emphysema
- Estimated collateral ventilation observed on CT scanned by VIDA vision software (VIDA vision®, VIDA Diagnostics, Iowa-USA) - Fissure integrity on target lobe less than 75%.
- Use of continuous systemic corticosteroid therapy> 20mg QD (quaque die, once a day) of prednisone (or equivalent)
- Active lung or extra pulmonary infection
- Coronary heart disease and/or severe ventricular dysfunction
- Significant renal or hepatic disease
- Immunosuppressive disease
- Rheumatologic or orthopedic disease limiting physical capacity;
- Cognitive inability to understand study procedures;
- Impression by clinical research investigators with a lifespan of less than a year1;
- Active smoking
- Malignant neoplasia with estimated prognosis of survival <2 years
- Psychosocial problems
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endobronchial valve + marrow-derived mesenchymal stromal cell
|
Endoscopic lung volume reduction therapy.
Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
|
Active Comparator: Endobronchial valve
|
Endoscopic lung volume reduction therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause death
Time Frame: 6 months
|
Expressed as the total number of death due to all conditions during the clinical trial.
|
6 months
|
Number of participants with worsening of dyspnea
Time Frame: 6 months
|
Number of participants with worsening of dyspnea as measured by the mMRC-Modified Medical Research Council (1 point increase in the measured scale).
The mMRC Dyspnea Scale quantifies disability attributable to breathlessness (range from 1-4), and is useful for characterizing baseline dyspnea in patients with respiratory diseases.
|
6 months
|
Number of participants with respiratory functional worsening
Time Frame: 6 months
|
Number of participants with respiratory functional worsening as measured by decrease of 15% or more in FEV1 (forced expiratory volume in one second).
FEV1 is a measurement taken from a pulmonary function test.
It calculates the amount of air that a person can force out of their lungs in 1 second.
|
6 months
|
Impairment of exercise capacity
Time Frame: 6 months
|
Impairment of exercise capacity as measured by reduction of 35 m in the 6-minute walk test.
The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.
The test provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
|
6 months
|
Increased oxygen use
Time Frame: 6 months
|
Outcome measure result: number of participants with 1 point increase in oxygen need as classification on the chart above 0 - no oxygen use 1- intermittent use <6h/day 2- intermittent use >6h/dia 3 - continuous oxygen use
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hugo G Oliveira, PhD, Hospital de Clinicas de Porto Alegre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-0327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease Severe
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University Hospital, ToursCompletedSevere Chronic Obstructive Pulmonary DiseaseFrance
-
Hospital de MataróCompleted
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Schön Klinik Berchtesgadener LandResMedCompletedChronic Obstructive Pulmonary Disease SevereGermany
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
Clinical Trials on Zephyr Endobronchial Valve
-
Pulmonx CorporationActive, not recruiting
-
Pulmonx CorporationRecruiting
-
Heidelberg UniversityHumboldt-Universität zu BerlinWithdrawn
-
Sherwood Forest Hospitals NHS Foundation TrustCompleted
-
Pulmonx International SàrlTerminatedPulmonary EmphysemaGermany
-
Chinese PLA General HospitalUnknownChronic Obstructive Pulmonary Disease | EmphysemaChina
-
Macquarie University, AustraliaCompletedChronic Obstructive Pulmonary Disease (COPD)Australia
-
Pulmonx CorporationCompletedPulmonary EmphysemaUnited Kingdom, Switzerland, Germany
-
Pulmonx CorporationActive, not recruiting
-
Asan Medical CenterCompletedPulmonary EmphysemaKorea, Republic of